Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.

[1]  T. Rüffer,et al.  Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents. , 2013, Dalton transactions.

[2]  W. Sheldrick,et al.  Rhodium(III) and iridium(III) complexes as anticancer agents , 2012 .

[3]  K. Y. Zhang,et al.  Iridium(III) complexes as therapeutic and bioimaging reagents for cellular applications , 2012 .

[4]  R. Phillips,et al.  Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents. , 2012, Dalton transactions.

[5]  S. Gómez‐Ruiz,et al.  Platinum(II/IV) complexes containing ethylenediamine-N,N'-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. , 2012, Metallomics : integrated biometal science.

[6]  S. Gómez‐Ruiz,et al.  Metals in Medicine , 2012, Bioinorganic chemistry and applications.

[7]  R. Paschke,et al.  Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties. , 2012, Journal of inorganic biochemistry.

[8]  P. Sadler,et al.  Organometallic Iridium(III) Cyclopentadienyl Anticancer Complexes Containing C,N-Chelating Ligands , 2011 .

[9]  P. Sadler,et al.  Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes. , 2011, Inorganic chemistry.

[10]  P. Sadler,et al.  Organometallic half-sandwich iridium anticancer complexes. , 2011, Journal of medicinal chemistry.

[11]  S. Wölfl,et al.  Cellular Selectivity and Biological Impact of Cytotoxic Rhodium(III) and Iridium(III) Complexes Containing Methyl‐Substituted Phenanthroline Ligands , 2011, ChemMedChem.

[12]  Ying Yan,et al.  Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells. , 2011, The Journal of clinical endocrinology and metabolism.

[13]  C. Wagner,et al.  On the Reactivity of the Platina-β-diketone [Pt2{(COMe)2H}2(μ-Cl)2] Towards Ph2PCH2CH2CH2SOxPh (x = 0, 2) , 2010 .

[14]  C. Hartinger.  Trapping unstable benzoquinone analogues by coordination to a [(η(5)-C(5)Me(5))Ir] fragment and the anticancer activity of the resulting complexes. , 2010, Angewandte Chemie.

[15]  P. Dyson,et al.  Discovery, structure, and anticancer activity of an iridium complex of diselenobenzoquinone. , 2010, Angewandte Chemie.

[16]  A. Casini,et al.  Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT. , 2010, Dalton transactions.

[17]  A. Casini,et al.  Anticancer activity of new organo-ruthenium, rhodium and iridium complexes containing the 2-(pyridine-2-yl)thiazole N,N -chelating ligand , 2010 .

[18]  B. Nawrot,et al.  Rhodium(III) and iridium(III) complexes with 1,2-naphthoquinone-1-oximate as a bidentate ligand: synthesis, structure, and biological activity , 2010, JBIC Journal of Biological Inorganic Chemistry.

[19]  P. Sadler,et al.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. , 2009, Drug discovery today.

[20]  Xin Meng,et al.  Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells , 2009, BMC Cancer.

[21]  Andrew D. Phillips,et al.  (Pentamethylcyclopentadienyl)iridium-PTA (PTA = 1,3,5-Triaza-7-phosphaadamantane) Complexes and Their Application in Catalytic Water Phase Carbon Dioxide Hydrogenation , 2008 .

[22]  R. Gust,et al.  Influence of the Polypyridyl (pp) Ligand Size on the DNA Binding Properties, Cytotoxicity and Cellular Uptake of Organoruthenium(II) Complexes of the Type [(η6‐C6Me6)Ru(L)(pp)]n+ [L = Cl, n = 1; L = (NH2)2CS, n = 2] , 2007 .

[23]  Bernhard Lippert,et al.  Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .

[24]  M. Jakupec,et al.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.

[25]  B. Marian,et al.  KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview. , 2005, International journal of clinical pharmacology and therapeutics.

[26]  M. Jakupec,et al.  Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. , 2005, Current medicinal chemistry.

[27]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[28]  Anthony L. Spek,et al.  Journal of , 1993 .

[29]  G. Sava,et al.  Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. , 2000, Pharmacology & toxicology.

[30]  A. Bergamo,et al.  Ruthenium-based compounds and tumour growth control (review). , 2000, International journal of oncology.

[31]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[32]  M J Clarke,et al.  Non-platinum chemotherapeutic metallopharmaceuticals. , 1999, Chemical reviews.

[33]  L. Helm,et al.  Water exchange on metal ions: experiments and simulations , 1999 .

[34]  P. Sadler,et al.  Metals in Medicine. , 1999, Angewandte Chemie.

[35]  M. Valderrama,et al.  Diphenylphosphino(phenylthio)methane as a monodentate or bidentate chelate ligand in rhodium, iridium and ruthenium complexes, 3rystal structure of [(η5-C5Me5) IrCl(η2-Ph2PCH2SPhP,S)]BF4·Me2CO , 1997 .

[36]  G. Sava,et al.  Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse , 1994, Clinical & Experimental Metastasis.

[37]  G. Chu,et al.  Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. , 1994, The Journal of biological chemistry.

[38]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[39]  R. Ball,et al.  Synthesis and structure of [(η-C5Me5)Ir(CO)]2 , 1990 .

[40]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[41]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.

[42]  A. Casini,et al.  Biological Properties of IRIM, the Iridium(III) Analogue of (Imidazolium (Bisimidazole) Tetrachlororuthenate) (ICR) , 2000, Metal-based drugs.